Provided by Tiger Trade Technology Pte. Ltd.

Protagonist Therapeutics

83.32
-1.1700-1.38%
Post-market: 83.320.00000.00%16:49 EST
Volume:322.02K
Turnover:26.77M
Market Cap:5.21B
PE:126.24
High:83.90
Open:83.47
Low:82.21
Close:84.49
52wk High:96.54
52wk Low:33.70
Shares:62.52M
Float Shares:43.15M
Volume Ratio:0.36
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6600
EPS(LYR):4.23
ROE:7.80%
ROA:1.82%
PB:8.07
PE(LYR):19.70

Loading ...

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.
·
Yesterday

Director’s Big Move: Major Insider Stock Sale Shakes Up Protagonist Therapeutics

TIPRANKS
·
Feb 07

Protagonist Therapeutics Director William D. Waddill Reports Sale of Common Shares

Reuters
·
Feb 07

Protagonist Therapeutics Is Maintained at Buy by Jefferies

Dow Jones
·
Feb 03

Protagonist Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 31

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Unicycive Therapeutics (UNCY)

TIPRANKS
·
Jan 30

Protagonist Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $117 From $80

THOMSON REUTERS
·
Jan 30

Arturo Molina, Chief Medical Officer, Reports Disposal of Protagonist Therapeutics Common Shares

Reuters
·
Jan 28

Have Insiders Sold Protagonist Therapeutics Shares Recently?

Simply Wall St.
·
Jan 23

Top Brass at Protagonist Therapeutics Quietly Cash In on Major Stock Moves

TIPRANKS
·
Jan 22

Protagonist Therapeutics CFO Asif Ali Reports Sale of Common Shares

Reuters
·
Jan 22

H.C. Wainwright Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

TIPRANKS
·
Jan 16

Protagonist Therapeutics (PTGX) Valuation Check After Strong Multi Year Return And Recent Share Price Pullback

Simply Wall St.
·
Jan 16

High Growth Tech Stocks In The US For January 2026

Simply Wall St.
·
Jan 09

Protagonist Therapeutics to Present Company Overview at J.P. Morgan Healthcare Conference

Reuters
·
Jan 07

Protagonist Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
Jan 05

Truist Adjusts Price Target on Protagonist Therapeutics to $110 From $88, Maintains Buy Rating

MT Newswires Live
·
Jan 05

Takeda Submits NDA to FDA for Rusfertide in Polycythemia Vera

Reuters
·
Jan 05

Takeda and Protagonist Announce Submission of New Drug Application (Nda) for Rusfertide for Treatment of Polycythemia Vera (Pv)

THOMSON REUTERS
·
Jan 05

Protagonist Therapeutics Inc : Truist Securities Raises Target Price to $110 From $88

THOMSON REUTERS
·
Jan 05